Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
11/2003
11/06/2003WO2002059108A8 Melanocortin receptor agonists
11/06/2003WO2002059107A8 Substituted piperidines/piperazines as melanocortin receptor agonists
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207852 Treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207794 Compounds which are alpha -halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable
11/06/2003US20030207772 Warming and nonirritating lubricant compositions and method of comparing irritation
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207347 Useful in treating ovarian, renal, neurological, cardiovascular disorders and modulating angiogenesis, cell proliferation
11/06/2003US20030206977 Natural tea for curing men's impotence and a method for manufacturing the same
11/06/2003US20030206967 Sodium metasilicate, borax,sodium thiosulfate, potassium carbonate, refined cane sugar and water; improvement in disease resistance, weight gain rate, crop yield, crop quality, and harvest time
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483564A1 Chimeric camp factors for vaccination against streptococcus infection
11/06/2003CA2483554A1 Treatment of hypertension in women receiving hormone replacement therapy
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2481324A1 [1,4]diazocino [7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/05/2003EP1359215A1 Soya cell strains with high isoflavone content
11/05/2003EP1359156A2 Papilloma virus vaccine
11/05/2003EP1359152A2 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
11/05/2003EP1358869A1 Biologically active compounds for the modificaton of bodily odours
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358206A2 Peptide-based compounds
11/05/2003EP1358189A1 Process for the preparation of a pyrazolo 4,3-d]pyrimidine derivative
11/05/2003EP1358184A1 Substituted alkylamine derivatives and methods of use
11/05/2003EP1358180A2 Naphthostyril derivatives and their use as inhibitors of cyclin-dependent kinases
11/05/2003EP1358169A2 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
11/05/2003EP1358163A1 Melanocortin receptor agonists
11/05/2003EP1358161A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
11/05/2003EP1358150A1 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
11/05/2003EP1357930A2 Histidine-rich glycoprotein
11/05/2003EP1357929A2 Modulation of immune response and methods based thereon
11/05/2003EP1357920A2 Compositions and method of tissue superoxygenation
11/05/2003EP1357915A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/05/2003EP1357909A1 Il-8 receptor antagonists
11/05/2003EP1357908A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
11/05/2003EP1357904A2 Use of pyrazolo 4,3-d]pyrimidines
11/05/2003EP1357903A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO b]THIOPHENE AND SALTS THEREOF
11/05/2003EP1357897A2 Delivery of biologically active agents
11/05/2003EP1357871A1 Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
11/05/2003EP1268480B1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
11/05/2003EP1140113B1 Use of bisphosphonates for the prevention and treatment of infectious processes
11/05/2003EP1054857B1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
11/05/2003EP1003520B1 Hydroxy-prostaglandin derivatives for the treatment of erectile dysfunction
11/05/2003EP0839145B1 Heterocyclylcarboxamide derivatives and their use as therapeutic agents
11/05/2003CN1454256A The high bone mass gene of 11q13.3
11/05/2003CN1454204A IL-8 receptor antagonists
11/05/2003CN1454091A Immunostimulatory nucleic acids
11/05/2003CN1453031A Externally-applied medicine composition for treating mastoproliferation and its prepn
11/05/2003CN1453012A Chinese medicine for health of women in menstrual period
11/05/2003CN1126554C Injecta for treating mammary gland lobule hyperplasia
11/04/2003US6642410 Useful as antiproliferative agents, including, for example, anticancer agents
11/04/2003US6642369 Nucleic acids involved in the responder phenotype and applications thereof
11/04/2003US6642267 Side effect reduction over opioid analgesics; analgesic and/or anxiolytic action
11/04/2003US6642250 1,8-naphthyridin-2(1H)-one derivatives
11/04/2003US6642242 Quinoline and quinazoline compounds useful in therapy
11/04/2003US6642223 Benzoheterocyclic derivatives
11/04/2003US6642222 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/04/2003US6642219 Treating intermenstrual bleeding in female induced by administration of progestogen-only contraceptive regimen on continuous daily basis, by co-administering, for at least 28 consecutive days, anti-progestogen at specified daily dose
11/04/2003US6642212 Health supplement comprising naturally occurring phytoestrogen selected from any two or more of genistein, daidzein and/or their glycosides
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6642008 Assays and therapies for latent viral infection
11/04/2003US6641526 Development of normal offspring from oocytes injected with freeze-dried spermatozoa
10/2003
10/31/2003CA2444598A1 Compositions useful as inhibitors of gsk-3
10/30/2003WO2003089438A1 Labeled oxazinocarbazoles as diagnostic agents
10/30/2003WO2003089419A1 New 2-substituted -1,3-thiazole compounds
10/30/2003WO2003089409A1 Compounds having affinity at 5ht2c receptor and use thereof in therapy
10/30/2003WO2003089002A1 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
10/30/2003WO2003089001A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
10/30/2003WO2003088974A1 Pharmaceutical composition
10/30/2003WO2003088970A2 Modulators of hedgehog signaling pathways, compositions and uses related thereto
10/30/2003WO2003088945A1 Aerosol containing a particulate active substance
10/30/2003WO2003088927A2 Novel curcumin analogues and uses thereof
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088880A2 Condom
10/30/2003WO2003053330A3 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
10/30/2003WO2003031568A3 Intracellular signaling molecules
10/30/2003WO2003028527A3 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
10/30/2003WO2003025199A3 Mid 4460, a human tyrosine phosphatase family member and uses therefor
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 557